← Back to Trial

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

Trial Locations

• Research Site Dothan, Alabama, United States
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Phoenix, Arizona, United States
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Duarte, California, United States
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Irvine, California, United States
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Newport Beach, California, United States
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site San Francisco, California, United States
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Aurora, Colorado, United States
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Miami, Florida, United States
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site O'Fallon, Illinois, United States
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Metairie, Louisiana, United States
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Westbrook, Maine, United States
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Detroit, Michigan, United States
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Grand Rapids, Michigan, United States
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site St Louis, Missouri, United States
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Omaha, Nebraska, United States
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Albuquerque, New Mexico, United States
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site New Hyde Park, New York, United States
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site New York, New York, United States
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Cleveland, Ohio, United States
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Cleveland, Ohio, United States
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Dayton, Ohio, United States
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Portland, Oregon, United States
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Pittsburgh, Pennsylvania, United States
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Myrtle Beach, South Carolina, United States
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Nashville, Tennessee, United States
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Houston, Texas, United States
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Salt Lake City, Utah, United States
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Tacoma, Washington, United States
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Darlinghurst, Australia
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Kurralta Park, Australia
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Melbourne, Australia
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Murdoch, Australia
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Linz, Austria
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Salzburg, Austria
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Vienna, Austria
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Ghent, Belgium
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Leuven, Belgium
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Liège, Belgium
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site São Paulo, Brazil
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site São Paulo, Brazil
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Edmonton, Alberta, Canada
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Halifax, Nova Scotia, Canada
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Hamilton, Ontario, Canada
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Toronto, Ontario, Canada
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Toronto, Ontario, Canada
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Montreal, Quebec, Canada
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Montreal, Quebec, Canada
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Beijing, China
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Beijing, China
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Chengdu, China
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Chongqing, China
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Fuzhou, China
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Guangzhou, China
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Guangzhou, China
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Guangzhou, China
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Hangzhou, China
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Hangzhou, China
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Hangzhou, China
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Jinan, China
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Nanjing, China
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Nanjing, China
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Shanghai, China
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Shanghai, China
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Shenyang, China
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Suzhou, China
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Wuhan, China
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Wuhan, China
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Xi'an, China
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Kuopio, Finland
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Villejuif, France
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Augsburg, Germany
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Berlin, Germany
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Bonn, Germany
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Cologne, Germany
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Dresden, Germany
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Essen, Germany
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Jena, Germany
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Karlsruhe, Germany
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site München, Germany
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Münster, Germany
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Nuremberg, Germany
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Rostock, Germany
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Stuttgart, Germany
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Tübingen, Germany
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Würzburg, Germany
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Bangalore, India
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Gūrgaon, India
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Gūrgaon, India
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Navi Mumbai, India
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Haifa, Israel
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Jerusalem, Israel
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Petah Tikva, Israel
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Ramat Gan, Israel
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Tel Aviv, Israel
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Milan, Italy
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Milan, Italy
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Misterbianco, Italy
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Naples, Italy
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Negrar, Italy
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Reggio Emilia, Italy
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Rozzano, Italy
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Chiba, Japan
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Chūōku, Japan
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Fukuoka, Japan
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Hamamatsu, Japan
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Kamakura-shi, Japan
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Kanazawa, Japan
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Kashiwa, Japan
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Kobe, Japan
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Kyoto, Japan
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Sapporo, Japan
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Suita-shi, Japan
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Yokohama, Japan
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Amsterdam, Netherlands
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Nijmegen, Netherlands
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Gdansk, Poland
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Krakow, Poland
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Warsaw, Poland
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Goyang-si, South Korea
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Seoul, South Korea
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Seoul, South Korea
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Seoul, South Korea
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Seoul, South Korea
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Seoul, South Korea
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Barcelona, Spain
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Barcelona, Spain
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site L'Hospitalet de Llobregat, Spain
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Madrid, Spain
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Majadahonda, Spain
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Málaga, Spain
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Santiago de Compostela, Spain
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Stockholm, Sweden
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Umeå, Sweden
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Bern, Switzerland
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Geneva, Switzerland
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Zurich, Switzerland
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Kaohsiung City, Taiwan
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Taipei, Taiwan
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Taipei, Taiwan
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Taipei, Taiwan
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Taoyuan, Taiwan
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Bangkok, Thailand
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Bangkok, Thailand
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Ankara, Turkey (Türkiye)
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Ankara, Turkey (Türkiye)
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Istanbul, Turkey (Türkiye)
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Istanbul, Turkey (Türkiye)
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site London, United Kingdom
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Middlesbrough, United Kingdom
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Southampton, United Kingdom
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)
• Research Site Truro, United Kingdom
  • Contact: AstraZeneca Clinical Study Information Center · 1-877-240-9479 · [email protected] (opens in new tab)